Business Wire

BOOST.AI

11.5.2023 09:02:35 CEST | Business Wire | Press release

Share
Boost.ai Unveils Large Language Model Enhancements to Conversational AI Platform

Boost.ai, a leading conversational AI solution provider, today announced Version 12 of its platform, the first of a series of planned updates by the company to incorporate Large Language Model (LLM)-enriched features. This iteration is focused on key customer experience (CX) improvements, including content suggestion, content rewriting and accelerated generation of training data. The new update will take advantage of Generative AI to suggest messaging content to AI Trainers within the boost.ai platform, generating suggested responses and resulting in drastically reduced implementation times for new intents. With this latest release, boost.ai reinforces its commitment to researching, developing, releasing, and maintaining responsible implementations of LLM-powered, enterprise-quality conversational AI features in order to further enhance the customer experience.

ChatGPT has dominated headlines throughout 2023, yet questions about the accuracy of its underlying models, GPT-3.5 and GPT-4, persist. With an 85% accuracy rate, LLMs are a good indication of the potential of this technology in consumer-facing applications, but in their current raw state they lack the dependency for integration directly into a bank or insurance firm's systems. Boost.ai helps to resolve this issue by seamlessly integrating the predictive capabilities of LLMs with enterprise-grade control of their conversational AI platform, creating a Hybrid Natural Language Understanding (NLU) system that offers unmatched accuracy, flexibility, and cost-effectiveness. Expertly weaving together the right AI components for each task, boost.ai’s platform ensures precise and accurate answers - harnessing the benefits of LLMs, while still adhering to stringent quality assurance requirements.

“LLM technology offers great promise, but most applications just aren’t properly designed to securely and scalably support real-world businesses. With worries about accuracy or even inappropriate behavior, established institutions like banks could not risk direct access to this iteration of generative AI - until now,” said Jerry Haywood, CEO of boost.ai. “By pairing LLMs with our conversational AI, we’re able to ensure accuracy and open the door for customers in sensitive industries like financial services. We’re proud to be pioneering a way forward for businesses to harness this tech right now. It’s available for customers to use and enhance their existing solution, and to help them achieve speed to value significantly sooner whilst minimizing the risks currently dominating headlines.”

With a Hybrid NLU approach, enterprises gain the ability to combine boost.ai’s market-leading intent management, context handling, and dialogue management solutions with powerful LLM-enriched tools. Boost.ai’s existing intent engine is highly trained with guardrails in place to help guide the LLM, increasing overall accuracy and reducing the number of false positives. The end result is a chatbot that can confidently provide answers to inquiries, and a more streamlined development path that radically enhances how boost.ai customers can build scalable customer experiences for chat and voice.

“With our Hybrid NLU, we’ve been able to surpass the performance of either model on its own, providing our customers with the best of both worlds,” said Lars Ropeid Selsås, Founder of boost.ai. “Boost.ai will continue to operate at the cutting edge of AI possibility, refining our platform so that our customers are always receiving the best possible technology and service.”

On May 9th, Boost.ai co-founder, Henry Vaage Iversen and the technical team conducted a webinar highlighting the strengths of Hybrid NLU and mapping out a path for businesses to start using LLM technology to their advantage. For a recording of the full webinar, please visit: https://www.boost.ai/webinars/enhancing-cx-and-reducing-operational-costs-with-boost-ai-large-language-models

About Boost.ai

Boost.ai is a global leader in conversational AI optimized for scale. Boasting the industry's most robust intent portfolio, Boost.ai is pioneering an era of broad-scope virtual agents to deliver the most advanced and scalable technology on the market. With consistent resolution rates of 90%, Boost.ai’s market-leading virtual agent supports enterprise customers across key industries throughout the United States and Europe, including banking, insurance, telecom, retail and more. In 2021, Boost.ai was named a major player in the IDC MarketScape category, Worldwide Conversational AI Platforms for Customer Service. Key customers include Santander Bank, MSU Federal Credit Union, Aspire General Services, Tokio Marine and more. Learn more at boost.ai.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005082/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release

Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye